Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001415889-25-008259
Filing Date
2025-03-17
Accepted
2025-03-17 19:58:15
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 18079
2 JOINT FILING AGREEMENT ex-99-03172025_110314.htm EX-99.1 4571
  Complete submission text file 0001415889-25-008259.txt   24478
Mailing Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116
Business Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116 617-778-2500
RA CAPITAL MANAGEMENT, L.P. (Filed by) CIK: 0001346824 (see all company filings)

EIN.: 830406777 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087
Business Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087 (888) 378-6240
Mineralys Therapeutics, Inc. (Subject) CIK: 0001933414 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-94000 | Film No.: 25746113
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)